Test Price
2,800 AED✅ Home Collection Available
ST3GAL3 Gene (Early Infantile Epileptic Encephalopathy Type 15) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
At a Glance
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
- Clinical Guidance: Dedicated telephonic post-test counselling with a licensed genetic specialist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Code: ST3GAL3-NGS-01 | Category: Paediatric Neurology – Genetic Epilepsy Panel
Test Overview & Methodology
The ST3GAL3 gene NGS test analyses the entire coding region for mutations linked to early infantile epileptic encephalopathy type 15, a severe neonatal-onset epilepsy syndrome. This comprehensive assay detects single nucleotide variants, small insertions/deletions, and copy number variations across all exons and flanking intronic regions, providing definitive molecular diagnosis for targeted clinical management.
Pre-Test Requirement: A mandatory genetic counselling session is required prior to sample collection. You will be asked to provide a detailed three-generation family history to construct a pedigree chart, ensuring accurate variant interpretation per DHA standards. Our genetic counsellor will guide you through the process, discuss potential outcomes, and address any questions about inheritance patterns.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity | Standard panel may miss novel variants |
| Method | NGS (Next-Generation Sequencing) full gene analysis | Sanger sequencing of selected exons |
| Turnaround | 21–28 business days with integrated counselling | 28–42 business days, counselling separate |
| Variant Detection | SNVs, indels, CNVs & splice-site variants | Limited to known hotspot mutations |
Physician Insight & Safety Protocols
Consultant Medical Genetics | DHA Registration ID: 9294403
"As a clinical geneticist specializing in paediatric neurogenetics, I understand the profound uncertainty families experience when seeking answers for their child's seizures. This comprehensive ST3GAL3 gene analysis provides the molecular clarity needed to guide targeted therapeutic decisions, offer prognostic counselling, and enable informed family planning. I emphasise that all results must be interpreted within the full clinical context by a paediatric neurologist, and that genetic testing complements—never replaces—standard EEG and neuroimaging evaluations."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics
Advisory: Medication Safety
Important: Do not discontinue or alter prescribed anti-seizure medication without direct consultation with your treating physician. Abrupt cessation can precipitate status epilepticus, a life-threatening emergency. Medication adjustments must be carefully supervised and gradually weaned under medical guidance.
Exclusion Criteria & Emergency Red Flags
- Emergency: Patients experiencing acute seizure clusters or a single seizure lasting longer than 5 minutes must seek immediate emergency medical care—genetic testing should not delay urgent treatment.
- Not a Substitute: This test does not replace standard EEG monitoring, neuroimaging (MRI/CT), or acute metabolic workup in a seizing infant.
- Minor Consent: Testing on minors requires written informed consent from a parent or legal guardian, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Data Governance: All genetic data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Patient FAQ & Clinical Guidance
1. What does the ST3GAL3 gene test detect?
This NGS-based test sequences the entire coding region of the ST3GAL3 gene to identify disease-causing mutations responsible for early infantile epileptic encephalopathy type 15 (EIEE15). It detects single nucleotide variants, small insertions and deletions, and copy number changes that standard targeted panels may miss, providing a comprehensive molecular diagnosis.
2. How should I prepare my child for testing?
No fasting or medication changes are required. A simple blood draw or buccal swab is sufficient for analysis. Our paediatric-trained phlebotomist will perform the collection in the comfort of your home to minimise stress. Please have your child's detailed clinical history, prior EEG reports, and any neuroimaging results ready for the pre-test genetic counselling session.
3. What do the results mean for my child's treatment plan?
A positive result confirms the diagnosis of EIEE15, enabling personalised anti-seizure therapy selection, access to targeted clinical trials, and accurate prognostic counselling for your family. A negative result does not rule out genetic epilepsy and may prompt further investigation through whole-exome or whole-genome sequencing. Your genetic counsellor and paediatric neurologist will discuss the implications in detail.
4. How long does it take to get results?
Results are typically available within 21 to 28 business days from sample receipt. The timeline includes comprehensive bioinformatics analysis, variant classification per ACMG guidelines, and integrated genetic counselling for result disclosure. Urgent cases may be expedited upon request; please contact our team for details.
5. Is genetic counselling included in the test price?
Yes. The 2,800 AED fee includes a mandatory pre-test genetic counselling session, the full NGS analysis, variant interpretation, and a dedicated post-test telephonic counselling appointment with our consultant medical geneticist to review results and answer your questions. This ensures you fully understand the implications for your child and family.
6. Can this test be done during pregnancy?
This specific test is designed for postnatal diagnosis in infants and children presenting with seizures. For prenatal testing of ST3GAL3 mutations, please consult our prenatal genetics team for amniocentesis or chorionic villus sampling options, which require separate counselling and consent procedures under UAE law.
UAE Regulatory & Data Privacy Adherence
Your Data, Your Rights — Full Regulatory Compliance
DNA Labs UAE operates under the strict oversight of the Dubai Health Authority (DHA) and adheres to all applicable federal laws governing genetic data and patient privacy:
- Data Protection: All genetic information is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring your data is collected with explicit consent, used only for diagnostic purposes, and never shared without your authorisation.
- Health Information Governance: Our laboratory information systems meet the security standards mandated by Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, guaranteeing encrypted storage, secure transmission, and strict access controls.
- Clinical Safety & Patient Consent: All testing procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability, which governs informed consent, medical professional accountability, and patient safety protocols across the UAE healthcare system.
- DHA Licensing: Our facility is fully licensed by the Dubai Health Authority (License No. 1143) and undergoes regular inspections to maintain accreditation and uphold the highest standards of clinical quality and laboratory practice.
Clinical & Logistical Metadata
| Test Name | ST3GAL3 Gene (Early Infantile Epileptic Encephalopathy Type 15) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 21–28 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Buccal Swab — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available (Daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) — Full Gene Coding Region & Flanking Intronic Analysis |
| ICD-10-CM Code | G40.4 (Other generalized epilepsy and epileptic syndromes) |
| LOINC Code | 21636-6 (DNA sequence analysis of a specific gene) |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians